Table 2 HCV assessment at recruitment and treatment according for First Nations Peoples and non-Indigenous Australians
First Nations Peoples | Non-Indigenous Australians | ||
|---|---|---|---|
N = 89 | N = 3206 | p value | |
Genotype | |||
G1 | 49 (55.1%) | 1723 (53.7%) | 0.19‡ |
G3 | 28 (31.5%) | 1208 (37.7%) | |
Other | 12 (13.5%) | 275 (8.6%) | |
Duration of HCV infection in years (mean, SD)a | 20.75 (13.13) | 22.80 (11.96) | 0.14 |
Viral load IU/mlb (median, IQR) | 1,220,000 (281,000–4,230,000) | 1,258,925 (351,000–3,740,000) | 0.83€ |
Mode of HCV Acquisitionc | |||
Injection drug use | 67 (75.3%) | 2152 (67.2%) | 0.11‡ |
Tattoo | 27 (30.3%) | 525 (16.4%) | < 0.001‡ |
Blood transfusion | 8 (9.0%) | 284 (8.9%) | 0.97‡ |
HCV treatment prior to DAA-era | 9 (10.1%) | 651 (20.3%) | 0.018‡ |
Regimen | |||
PEGIFN/IFN ± RBV | 8 (88.9%) | 486 (74.7%) | 1.00¥ |
1st generation PEGIFN/protease inhibitors | 1 (11.1%) | 86 (13.2%) | |
DAA ± RBV | 0 (0.0%) | 19 (2.9%) | |
RCT not brought forward or not otherwise specified | 0 (0.0%) | 60 (9.2%) | |
Treatment response | |||
SVR (presumed re-infection) | 0 (0.0%) | 8 (1.2%) | 0.55¥ |
Relapse | 2 (22.2%) | 257 (39.5%) | |
Non-responder | 6 (66.7%) | 313 (48.1%) | |
Unknown | 1 (11.1%) | 73 (11.2%) | |
HCV DAA therapy regimen | |||
Sofosbuvir/Ledipasvir | 28 (31.5%) | 1276 (39.8%) | 0.13¥ |
Sofosbuvir + Daclastavir | 22 (24.7%) | 926 (28.9%) | |
Sofosbuvir/Velpatasvir | 19 (21.3%) | 557 (17.4%) | |
Sofosbuvir + Ribavirin | 3 (3.4%) | 93 (2.9%) | |
Elbasvir/Grazoprevir | 9 (10.1%) | 165 (5.1%) | |
Glecaprevir/Pibrentasvir | 7 (7.9%) | 107 (3.3%) | |
Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir | 1 (1.1%) | 61 (1.9%) | |
Sofosbuvir/Velpatasvir/Voxilaprevir | 0 (0.0%) | 5 (0.2%) | |
Miscellaneous DAAs | 0 (0.0%) | 16 (0.5%) | |
Treatment included ribavirind | 1 (1.1%) | 86 (2.7%) | 0.73¥ |
Lost to follow-up | |||
No LTFU | 64 (71.9%) | 2846 (88.8%) | < 0.001‡ |
LTFU | 25 (28.1%) | 360 (11.2%) | |